Leeward Investments LLC MA Has $6.83 Million Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA lessened its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 37.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 376,104 shares of the life sciences company's stock after selling 224,104 shares during the period. Leeward Investments LLC MA owned about 0.48% of Integra LifeSciences worth $6,834,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Texas Permanent School Fund Corp grew its holdings in shares of Integra LifeSciences by 1.5% during the first quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company's stock valued at $2,110,000 after purchasing an additional 870 shares during the last quarter. Duality Advisers LP raised its holdings in shares of Integra LifeSciences by 103.6% during the first quarter. Duality Advisers LP now owns 59,916 shares of the life sciences company's stock valued at $2,124,000 after acquiring an additional 30,484 shares during the period. Quantbot Technologies LP boosted its position in shares of Integra LifeSciences by 235.1% in the first quarter. Quantbot Technologies LP now owns 43,991 shares of the life sciences company's stock worth $1,559,000 after buying an additional 30,865 shares during the period. Concurrent Investment Advisors LLC grew its stake in Integra LifeSciences by 17.3% during the 1st quarter. Concurrent Investment Advisors LLC now owns 16,943 shares of the life sciences company's stock valued at $601,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Inspire Investing LLC increased its stake in Integra LifeSciences by 14.8% in the 1st quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company's stock valued at $360,000 after buying an additional 1,311 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

IART traded down $0.43 during trading on Friday, hitting $25.08. The stock had a trading volume of 324,671 shares, compared to its average volume of 1,100,972. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The company has a 50 day moving average price of $18.99 and a 200-day moving average price of $24.41. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -283.44, a P/E/G ratio of 0.82 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.25%. The business's quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the firm earned $0.76 EPS. As a group, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. Morgan Stanley increased their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an "underweight" rating in a research report on Monday, July 15th. JMP Securities decreased their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating on the stock in a research note on Tuesday, July 30th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Finally, Bank of America lowered their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.